Mir-141-3p Regulates Apoptosis and Mitochondrial Membrane Potential via Targeting Sirtuin1 in a 1-Methyl-4-Phenylpyridinium in vitro Model of Parkinson’s Disease

Figure 2

MPP+-induced neurotoxicity in the differentiated PC12 cell model. (a) Differentiated PC12 cells were treated with MPP+ (800 μM, 24 h), and MTT assays were used to determine cell viability. The results showed that cell viability decreased significantly after MPP+ treatment for 4 days. (b) Cells were stained with annexinV/PI, and apoptosis percentage was analyzed by flow cytometry. The results showed that the apoptosis percentage was increased significantly after MPP+ treatment. The upper and lower right quadrants (late and early apoptosis) were used for estimation of the apoptotic percentage. (c) Cells were stained with the CellROX Deep Red Reagent, and ROS generation was determined by flow cytometry. ROS production was increased after MPP+ treatment. (d) Western blot showed that MPP+ treatment decreased the SIRT1 protein expression and increased α-synuclein and the Nos1 expression. (e) Immunofluorescence of α-synuclein in control and MPP+-treated PC12 cells. . Error bars indicate standard deviation (SD).

(a)

(b)

(c)

(d)

(e)